Orexo and SVF Vaccines collaborate to explore AmorphOX® formulation of LNP-mRNA vaccines

The Medical News ·
Health & Medicine United Kingdom

Orexo AB and SVF Vaccines AB today announced a research collaboration to investigate whether Orexo’s proprietary powder-based drug delivery technology, AmorphOX®, can be used to develop stable powder-based formulations of lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) vaccines.

Read original article on The Medical News →

Related news